Tiagabine


GAT-1 selective GABA reuptake inhibitor

A nipecotic acid derivative selective GABA reuptake inhibitor; the prototype GAT-1 transporter blocker.

Abstract

Tiagabine ((R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid; CAS 115103-54-3; molecular formula C20H25NO2S2; molecular weight 375.55) is a nipecotic acid derivative selective inhibitor of the GABA transporter GAT-1, developed at Novo Nordisk and approved by the FDA in 1997 under the trade name Gabitril. Mechanism: high-affinity inhibition of GAT-1 (the principal neuronal GABA reuptake transporter) prolongs synaptic GABA availability after release, enhancing GABA-A and GABA-B receptor activation. Selectivity for GAT-1 over GAT-2 and GAT-3 is greater than 100-fold. Plasma half-life is 7 to 9 hours; metabolism is via CYP3A4. Approved as adjunctive therapy in partial-onset seizures in patients aged 12 and older. Off-label use in generalized anxiety disorder has been complicated by FDA warnings of new-onset seizures in patients without epilepsy (incidence approximately 1 percent at off-label doses). Used as the canonical GAT-1 selective inhibitor in mechanism studies.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph